经皮冠脉介入术(PCI)后使用双联抗血小板策略可以减少再次发生缺血几率,但也可能增加出血风险,术后双抗血小板(DAPT)至少一年已经成为共识,但一年后患者是否应该继续服用双抗药物?近日,来自美国贝斯以色列女执事医疗中心的Yeh教授等在JAMA网站上发表的一项研究也许 The use of dual antiplatelet strategies after percutaneous coronary intervention (PCI) may reduce the risk of recurrent ischemia, but may also increase the risk of bleeding and at least one year after surgery has become the consensus, but one year later Patients should continue to take dual anti-drug? Recently, from the United States Beth Israel Deaconess Medical Center, Yeh, Professor and other JAMA website published in a study may